AI Article Synopsis
- - The discovery of molecular changes related to cancer development is progressing quickly, leading to new targeted therapies in oncology.
- - High-throughput sequencing techniques are helping to identify genetic targets and biomarkers that predict how well patients will respond to these therapies.
- - The review highlights current clinical uses of pharmacogenetic markers, which are genetic variations in a person's DNA that can optimize chemotherapy use, along with recent developments in pharmacogenomics focused on both constitutional and tumor genomes.
Article Abstract
The discovery of molecular alterations involved in oncogenesis is evolving rapidly and has led to the development of new innovative targeted therapies in oncology. High-throughput sequencing techniques help to identify genomic targets and to provide predictive molecular biomarkers of response to guide alternative therapeutic strategies. Besides the emergence of these theranostic markers for the new targeted treatments, pharmacogenetic markers (corresponding to genetic variants existing in the constitutional DNA, i.e., the host genome) can help to optimize the use of chemotherapy. In this review, we present the current clinical applications of constitutional PG and the recent concepts and advances in pharmacogenomics, a rapidly evolving field that focuses on various molecular alterations identified on constitutional or somatic (tumor) genome.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.therap.2021.11.003 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!